Ilika plc with ticker (LON:IKA) now has a potential upside of 258.2% according to Berenberg Bank.
Berenberg Bank set a target price of 120 GBX for the company, which when compared to the Ilika plc share price of 34 GBX at opening today (29/12/2023) indicates a potential upside of 258.2%. Trading has ranged between 23 (52 week low) and 72 (52 week high) with an average of 215,616 shares exchanging hands daily. The market capitalisation at the time of writing is £58,820,814.
Ilika plc is a United Kingdom-based company. The Company is engaged in developing and commercializing its cutting-edge solid-state batteries. The Company develops and commercializes its thin-film Stereax miniature solid-state batteries for powering implantable medical devices and industrial wireless sensors (IIoT) in specialist environments, as well as progressing the development of its large-format Goliath cells for electric vehicles (EV) and cordless appliances. It has a secured lease of approximately 1,600 square meters property for Stereax manufacturing scale-up and installed over 340 square meters clean room facility. The Company is enabling solutions for applications, such as industrial Internet of things (IoT), MedTech, electric vehicles (EV) and consumer electronics. The Company has its operations in the United States of America, China and Israel.
Ilika plc 258.2% potential upside indicated by Berenberg Bank
- Written by: Charlotte Edwards
Find more news, interviews, share price & company profile here for:
Latest Company News
Graeme Purdy, CEO of Ilika, outlines progress in manufacturing readiness and early customer shipments for the Stereax miniature solid-state battery, as well as ongoing grant-supported development and customer engagement for the Goliath EV battery programme.
Ilika has received its first commercial order for Stereax battery electrodes, marking the start of scaled production for medical device applications.
Ilika plc has crossed a commercial milestone with its first regular revenue stream from its Stereax battery line, according to Dr Tom McColm of Morphose Capital. With strong cash reserves, momentum on its Goliath platform, and growing interest from defence sectors, the next 12 months could be transformational.
Ilika CEO Graeme Purdy shares how the company has shifted from commissioning to customer deliveries of its Stereax batteries — and why its Goliath EV programme is designed to beat the commoditised market with faster charging and extended range.
Ilika reports unaudited half-year results to 31 October 2025, highlighting on-schedule delivery of key commercial milestones across its Stereax medical battery and Goliath EV battery programmes, alongside continued customer validation, pilot-line commissioning, and £4.2m fundraising to support its roadmap.
Ilika has received its first revenue-generating purchase order from Cirtec Medical for the supply of Stereax electrodes, marking the transition of their partnership into commercial production.
